New company brand identity and Chief Scientific Officer appointment reflect long-term focus on developing small molecule therapeutics that regulate conformation of challenging drug targets SOUTH SAN FRANCISCO, Calif. – May 27, 2020 – Biodesy Inc. today announced that it has changed its corporate name to BlueLight Therapeutics Inc., effective May 20, 2020, and appointed
Former Chief Operations Officer and Delta™ System developer Ariel Notcovich promoted to drive industry adoption of the company’s core biomolecule characterization platform SOUTH SAN FRANCISCO, Calif. – Sept. 10, 2018 – Biodesy, Inc., a next-generation biomolecule characterization company, today announced the promotion of Ariel G. Notcovich to Chief Executive Officer, and the completion of a
Nature Communications publication highlights new applications for highly-sensitive SHG technology SOUTH SAN FRANCISCO, Calif. – Nov. 20, 2017 – Biodesy, Inc., a leader in next-generation technologies measuring structure and structural changes at the molecular level, today announced that its Delta ® System was used to discover a novel mechanism involved in the earliest steps of viral infection. The collaborative study
Biodesy Appoints Dominique Bridon as Chief Executive Officer
Biodesy’s article, “Protein Conformational Changes Are Detected and Resolved Site Specifically by Second-Harmonic Generation” published in Biophysical Journal was announced as one of the most popular articles in the journal in 2015 at the Biophysical Society meeting.
Biodesy was featured in “The Shape of Proteins to Come,” an article recently published in The Translational Scientist.
2016 Prism Award recognizes product innovation and potential to tackle grand challenges of our time
Company signs 20th pharmaceutical service contract; funds to be used to commercialize the Biodesy™ Delta System
Biodesy™ Delta System and performance data to be presented at upcoming Society for Laboratory Automation & Screening Meeting
Biodesy, Inc. announced it entered into a research collaboration agreement with Amgen Inc. to support Amgen’s neuroscience drug discovery programs.
Frost & Sullivan proudly recognizes Biodesy as the recipient of the 2014 Technology Innovation Leadership Award for Protein Analysis
Series A investors include 5AM Ventures, Pfizer Venture Investments and Roche Venture Fund
Biodesy announced it has received a supplement to its Phase II Small Business Innovation Research (SBIR) Award from the National Science Foundation (NSF)
Come visit us at booth 121!
Presentations
“Fragment-Based Drug Discovery Campaigns with Protein Complexes that Mediate Protein-Protein Interactions”
Presented by Charles Wartchow, Novartis Institutes for Biomedical Research
Tuesday, April 9 at 10:35 am
“New Ways of Targeting K-Ras”
Presented by Frank McCormick, HDF Comprehensive Cancer Center, University of California San Francisco
Plenary Keynote: Thursday, April 11 at 8:55 am
Poster Presentations
“Discrimination of Kinase Conformational States upon Inhibitor Binding by Second-Harmonic Generation”
Presented by Tracy Young, Biodesy
Poster Session A: #A5 (Tuesday, April 9 – Wednesday, April 10)
“Second-Harmonic Generation Based Detection of Ligand-Induced Conformational Changes in STING”
Presented by Serra Elliott, Biodesy
Poster Session B: # B1 (Wednesday, April 10 – Thursday, April 11)
“Second-Harmonic Generation (SHG) – A Novel On-Target and High-Throughput Technology for Small Molecule Screening by Detecting Structural Changes of Target Biomolecules”
Presented by Biodesy
Symposia Session: #S2 (Friday, April 12) Located at the Hard Rock Hotel
We will be attending and presenting at the Fragment-based Lead Discovery Conference 2018. Check out the abstract for our presentation below.
Identification of allosteric modulators of KRas using second harmonic generation
We will be attending and presenting a poster at the 16th Annual Discovery on Target conference in Boston, MA.
We will be attending and presenting a poster at the EMBO Workshop – RNA: Structure Meets Function. Please check out our poster with the abstract below.
Detection of Ligand-Induced Conformational Changes in Oligonucleotides by Second-Harmonic Generation
We will be attending the COMPPA Symposium on Membrane Protein Production and Analysis. Please check out our poster highlighting some of work on membrane proteins with the abstract below.
We will be attending the 5th NovAliX Conference. Please see the abstract below of our poster highlighting some of our work on membrane proteins.
We will be presenting at the 23rd Annual Meeting of the RNA Society. Check out our abstract below.
Detection of Ligand-Induced Conformational Changes in Oligonucleotides by Second-Harmonic Generation
Please join us at the NYAS on May 22nd for our poster presentation:
Discrimination of kinase conformational states upon inhibitor binding by second harmonic generation
Where we show how SHG can be used to discriminate between conformational states of two full-length kinases and a pseudokinase upon binding to well-characterized tool compounds.
For appointments to discuss scientific or business opportunities please contact us at info@biodesy.com